首页> 外文期刊>CPT: Pharmacometrics & Systems Pharmacology >The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop
【24h】

The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop

机译:建模和仿真在药品开发和注册中的作用:EFPIA / EMA建模和仿真研讨会的成果

获取原文
           

摘要

AbstractThe European Medicines Agency (EMA) and the Federation of Pharmaceutical Industries and Associations (EFPIA) hosted a workshop on modeling and simulation (M&S).1 Representatives from industry, academia, and regulatory agencies from Europe and beyond discussed the role of M&S in the development and registration of medicinal products within plenary and breakout sessions (BOS). This manuscript summarizes the plenary discussion (Table 1) focusing on the European perspective. Deliverables from each BOS are included in separate papers.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e31; doi:10.1038/psp.2013.7; advance online publication 27 February 2013
机译:摘要欧洲药品管理局(EMA)和制药工业与协会联合会(EFPIA)举办了一次建模与仿真(M&S)研讨会。 1 来自欧洲及其他地区的行业,学术界和监管机构的代表在全体会议和分组会议(BOS)中讨论了M&S在药品开发和注册中的作用。该手稿总结了全会讨论(表1),重点讨论了欧洲的观点。每个BOS的可交付成果均包含在单独的论文中。CPT:Pharmacometrics&Systems Pharmacology(2013)2,e31; doi:10.1038 / psp.2013.7;提前在线出版物2013年2月27日

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号